Eterna Therapeutics

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

NTN Buzztime, Inc. is a provider of interactive entertainment and technology tailored for bars, restaurants, casinos, and senior living centers in the United States and Canada. Established in 1982 and based in Carlsbad, California, the company offers a tablet platform that features a variety of games, including trivia, card games, and sports-related competitions. NTN Buzztime also leases equipment, such as tablets and charging stations, and licenses its content for installation on third-party equipment. The company's offerings include Buzztime Entertainment On Demand (BEOND), which serves as a social mobile entertainment platform designed specifically for the hospitality industry. With over 4 million registered players participating in more than 50 million games annually, NTN Buzztime creates an engaging environment that encourages social interaction and marketing opportunities for its network of venues.

IRX Therapeutics is a biotechnology company focused on developing immune therapies aimed at activating the immune system to combat cancer and related diseases. Founded in 1994 and headquartered in New York, the company is dedicated to enhancing cancer treatment efficacy. Its lead platform technology, IRX-2, is designed to broadly restore immune function by counteracting cancer-induced immune suppression. By enabling physicians to stimulate a cellular immune response, IRX Therapeutics seeks to improve treatment outcomes for a variety of cancers and potentially extend patient survival. The company is committed to advancing novel therapies that can significantly impact the landscape of cancer treatment.